Autocrine prostaglandin E 2 signaling promotes tumor cell survival and proliferation in childhood neuroblastoma

PLoS ONE

Volumn 7, Issue 1, 2012, Pages

  Rasmuson, Agnes ^a   Kock, Anna ^a   Fuskevåg, Ole Martin ^b   Kruspig, Björn ^a   Simón Santamaría, Jaione ^c   Gogvadze, Vladimir ^a   Johnsen, John Inge ^a   Kogner, Per ^a   Sveinbjörnsson, Baldur ^a,c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^c UNIVERSITY OF TROMSØ   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

16,16 DIMETHYLPROSTAGLANDIN E2; 6 ISOPROPOXY 9 OXO 2 XANTHENECARBOXYLIC ACID; 7 [5 (4 BIPHENYLYLMETHOXY) 2 MORPHOLINO 3 OXOCYCLOPENTYL] 4 HEPTENOIC ACID; CALCIUM ION; CELECOXIB; CYCLIC AMP; CYCLOOXYGENASE 2; L 161982; MESSENGER RNA; ONO 8713; ONO AE3 240; PROSTAGLANDIN E RECEPTOR 1; PROSTAGLANDIN E RECEPTOR 2; PROSTAGLANDIN E RECEPTOR 3; PROSTAGLANDIN E RECEPTOR 4; PROSTAGLANDIN E2; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; PROTEIN KINASE B; SC 51322; UNCLASSIFIED DRUG; BIPHENYL DERIVATIVE; CALCIUM; CYCLOOXYGENASE 2 INHIBITOR; L-161982; THIOPHENE DERIVATIVE; TRIAZOLE DERIVATIVE;

ARTICLE; AUTOCRINE EFFECT; CALCIUM CELL LEVEL; CANCER CELL CULTURE; CELL GROWTH; CELL MEMBRANE; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPLASM; DRUG MECHANISM; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; NEUROBLASTOMA; NEUROBLASTOMA CELL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; DRUG ANTAGONISM; DRUG EFFECT; IN VITRO STUDY; METABOLISM; PHOSPHORYLATION; TANDEM MASS SPECTROMETRY; TUMOR CELL LINE; WESTERN BLOTTING;

16,16-DIMETHYLPROSTAGLANDIN E2; AUTOCRINE COMMUNICATION; BIPHENYL COMPOUNDS; BLOTTING, WESTERN; CALCIUM; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CYCLIC AMP; CYCLOOXYGENASE 2 INHIBITORS; DINOPROSTONE; HUMANS; IMMUNOHISTOCHEMISTRY; NEUROBLASTOMA; PHOSPHORYLATION; RECEPTORS, PROSTAGLANDIN E, EP1 SUBTYPE; RECEPTORS, PROSTAGLANDIN E, EP2 SUBTYPE; RECEPTORS, PROSTAGLANDIN E, EP3 SUBTYPE; RECEPTORS, PROSTAGLANDIN E, EP4 SUBTYPE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TANDEM MASS SPECTROMETRY; THIOPHENES; TRIAZOLES;

EID: 84856012333     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0029331     Document Type: Article

References (51)

1. Wang D, Dubois RN, (2010) Eicosanoids and cancer. Nat Rev Cancer 10: 181-193.
2. Reynolds LM, Dalton CF, Reynolds GP, (2001) Phospholipid fatty acids and neurotoxicity in human neuroblastoma SH-SY5Y cells. Neurosci Lett 309: 193-196.
3. Johnsen JI, Lindskog M, Ponthan F, Pettersen I, Elfman L, et al. (2004) Cyclooxygenase-2 is expressed in neuroblastoma, and nonsteroidal anti-inflammatory drugs induce apoptosis and inhibit tumor growth in vivo. Cancer Res 64: 7210-7215.
4. Brodeur GM, (2003) Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 3: 203-216.
5. Ponthan F, Wickstrom M, Gleissman H, Fuskevag OM, Segerstrom L, et al. (2007) Celecoxib prevents neuroblastoma tumor development and potentiates the effect of chemotherapeutic drugs in vitro and in vivo. Clin Cancer Res 13: 1036-1044.
6. Lau L, Hansford LM, Cheng LS, Hang M, Baruchel S, et al. (2007) Cyclooxygenase inhibitors modulate the p53/HDM2 pathway and enhance chemotherapy-induced apoptosis in neuroblastoma. Oncogene 26: 1920-1931.
7. Kaneko M, Kaneko S, Suzuki K, (2009) Prolonged low-dose administration of the cyclooxygenase-2 inhibitor celecoxib enhances the antitumor activity of irinotecan against neuroblastoma xenografts. Cancer Sci 100: 2193-2201.
8. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, et al. (2005) Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352: 1092-1102.
9. Fischer SM, Hawk ET, Lubet RA, Coxibs and other nonsteroidal anti-inflammatory drugs in animal models of cancer chemoprevention. Cancer Prev Res(Phila) 4: 1728-1735.
10. Bhattacharya M, Peri KG, Almazan G, Ribeiro-da-Silva A, Shichi H, et al. (1998) Nuclear localization of prostaglandin E2 receptors. Proc Natl Acad Sci U S A 95: 15792-15797.
11. Chell S, Kaidi A, Williams AC, Paraskeva C, (2006) Mediators of PGE2 synthesis and signalling downstream of COX-2 represent potential targets for the prevention/treatment of colorectal cancer. Biochim Biophys Acta 1766: 104-119.
12. Caren H, Kryh H, Nethander M, Sjoberg RM, Trager C, et al. (2010) High-risk neuroblastoma tumors with 11q-deletion display a poor prognostic, chromosome instability phenotype with later onset. Proc Natl Acad Sci U S A 107: 4323-4328.
13. Kempen EC, Yang P, Felix E, Madden T, Newman RA, (2001) Simultaneous quantification of arachidonic acid metabolites in cultured tumor cells using high-performance liquid chromatography/electrospray ionization tandem mass spectrometry. Anal Biochem 297: 183-190.
14. Mosmann T, (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63.
15. Jones RL, Giembycz MA, Woodward DF, (2009) Prostanoid receptor antagonists: development strategies and therapeutic applications. Br J Pharmacol 158: 104-145.
16. Midgley RS, McConkey CC, Johnstone EC, Dunn JA, Smith JL, et al. (2010) Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: final results of the VICTOR trial. J Clin Oncol 28: 4575-4580.
17. Koch A, Bergman B, Holmberg E, Sederholm C, Ek L, et al. (2011) Effect of celecoxib on survival in patients with advanced non-small cell lung cancer: a double blind randomised clinical phase III trial (CYCLUS study) by the Swedish Lung Cancer Study Group. Eur J Cancer 47: 1546-1555.
18. Baryawno N, Sveinbjornsson B, Eksborg S, Orrego A, Segerstrom L, et al. (2008) Tumor-growth-promoting cyclooxygenase-2 prostaglandin E2 pathway provides medulloblastoma therapeutic targets. Neuro Oncol 10: 661-674.
19. Kryh H, Caren H, Erichsen J, Sjoberg RM, Abrahamsson J, et al. (2011) Comprehensive SNP array study of frequently used neuroblastoma cell lines; copy neutral loss of heterozygosity is common in the cell lines but uncommon in primary tumors. BMC Genomics 12: 443.
20. Sugino Y, Misawa A, Inoue J, Kitagawa M, Hosoi H, et al. (2007) Epigenetic silencing of prostaglandin E receptor 2 (PTGER2) is associated with progression of neuroblastomas. Oncogene 26: 7401-7413.
21. Koppen A, Ait-Aissa R, Koster J, Ora I, Bras J, et al. (2008) Dickkopf-3 expression is a marker for neuroblastic tumor maturation and is down-regulated by MYCN. Int J Cancer 122: 1455-1464.
22. Breinig M, Rieker R, Eiteneuer E, Wertenbruch T, Haugg AM, et al. (2008) Differential expression of E-prostanoid receptors in human hepatocellular carcinoma. Int J Cancer 122: 547-557.
23. Miyata Y, Kanda S, Maruta S, Matsuo T, Sakai H, et al. (2006) Relationship between prostaglandin E2 receptors and clinicopathologic features in human prostate cancer tissue. Urology 68: 1360-1365.
24. Rask K, Zhu Y, Wang W, Hedin L, Sundfeldt K, (2006) Ovarian epithelial cancer: a role for PGE2-synthesis and signalling in malignant transformation and progression. Mol Cancer 5: 62.
25. Asano T, Shoda J, Ueda T, Kawamoto T, Todoroki T, et al. (2002) Expressions of cyclooxygenase-2 and prostaglandin E-receptors in carcinoma of the gallbladder: crucial role of arachidonate metabolism in tumor growth and progression. Clin Cancer Res 8: 1157-1167.
26. Takafuji VA, Evans A, Lynch KR, Roche JK, (2002) PGE(2) receptors and synthesis in human gastric mucosa: perturbation in cancer. Prostaglandins Leukot Essent Fatty Acids 66: 71-81.
27. Gustafsson A, Hansson E, Kressner U, Nordgren S, Andersson M, et al. (2007) Prostanoid receptor expression in colorectal cancer related to tumor stage, differentiation and progression. Acta Oncol 46: 1107-1112.
28. Lee JL, Kim A, Kopelovich L, Bickers DR, Athar M, (2005) Differential expression of E prostanoid receptors in murine and human non-melanoma skin cancer. J Invest Dermatol 125: 818-825.
29. Bhattacharya M, Peri K, Ribeiro-da-Silva A, Almazan G, Shichi H, et al. (1999) Localization of functional prostaglandin E2 receptors EP3 and EP4 in the nuclear envelope. J Biol Chem 274: 15719-15724.
30. Zhu T, Gobeil F, Vazquez-Tello A, Leduc M, Rihakova L, et al. (2006) Intracrine signaling through lipid mediators and their cognate nuclear G-protein-coupled receptors: a paradigm based on PGE2, PAF, and LPA1 receptors. Can J Physiol Pharmacol 84: 377-391.
31. Ma X, Kundu N, Ioffe OB, Goloubeva O, Konger R, et al. (2010) Prostaglandin E receptor EP1 suppresses breast cancer metastasis and is linked to survival differences and cancer disparities. Mol Cancer Res 8: 1310-1318.
32. Dorsam RT, Gutkind JS, (2007) G-protein-coupled receptors and cancer. Nat Rev Cancer 7: 79-94.
33. An S, Yang J, So SW, Zeng L, Goetzl EJ, (1994) Isoforms of the EP3 subtype of human prostaglandin E2 receptor transduce both intracellular calcium and cAMP signals. Biochemistry 33: 14496-14502.
34. Monteith GR, McAndrew D, Faddy HM, Roberts-Thomson SJ, (2007) Calcium and cancer: targeting Ca2+ transport. Nat Rev Cancer 7: 519-530.
35. Clark JD, Lin LL, Kriz RW, Ramesha CS, Sultzman LA, et al. (1991) A novel arachidonic acid-selective cytosolic PLA2 contains a Ca(2+)-dependent translocation domain with homology to PKC and GAP. Cell 65: 1043-1051.
36. Borland G, Smith BO, Yarwood SJ, (2009) EPAC proteins transduce diverse cellular actions of cAMP. Br J Pharmacol 158: 70-86.
37. Naviglio S, Caraglia M, Abbruzzese A, Chiosi E, Di Gesto D, et al. (2009) Protein kinase A as a biological target in cancer therapy. Expert Opin Ther Targets 13: 83-92.
38. Prasad KN, Cole WC, Yan XD, Nahreini P, Kumar B, et al. (2003) Defects in cAMP-pathway may initiate carcinogenesis in dividing nerve cells: a review. Apoptosis 8: 579-586.
39. Choi SY, Choi BH, Suh BC, Chae HD, Kim JS, et al. (2001) Potentiation of PGE(2)-mediated cAMP production during neuronal differentiation of human neuroblastoma SK-N-BE(2)C cells. J Neurochem 79: 303-310.
40. Johnsen JI, Segerstrom L, Orrego A, Elfman L, Henriksson M, et al. (2008) Inhibitors of mammalian target of rapamycin downregulate MYCN protein expression and inhibit neuroblastoma growth in vitro and in vivo. Oncogene 27: 2910-2922.
41. Opel D, Poremba C, Simon T, Debatin KM, Fulda S, (2007) Activation of Akt predicts poor outcome in neuroblastoma. Cancer Res 67: 735-745.
42. Chesler L, Schlieve C, Goldenberg DD, Kenney A, Kim G, et al. (2006) Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma. Cancer Res 66: 8139-8146.
43. Li Z, Oh DY, Nakamura K, Thiele CJ, (2010) Perifosine-induced inhibition of akt attenuates brain-derived neurotrophic factor/TrkB-induced chemoresistance in neuroblastoma in vivo. Cancer.
44. Segerstrom L, Baryawno N, Sveinbjornsson B, Wickstrom M, Elfman L, et al. (2011) Effects of small molecule inhibitors of PI3K/Akt/mTOR signaling on neuroblastoma growth in vitro and in vivo. Int J Cancer 129: 2958-2965.
45. Sartelet H, Oligny LL, Vassal G, (2008) AKT pathway in neuroblastoma and its therapeutic implication. Expert Rev Anticancer Ther 8: 757-769.
46. Castellone MD, Teramoto H, Williams BO, Druey KM, Gutkind JS, (2005) Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis. Science 310: 1504-1510.
47. Wang D, Wang H, Shi Q, Katkuri S, Walhi W, et al. (2004) Prostaglandin E(2) promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferator-activated receptor delta. Cancer Cell 6: 285-295.
48. Watanabe K, Kawamori T, Nakatsugi S, Ohta T, Ohuchida S, et al. (1999) Role of the prostaglandin E receptor subtype EP1 in colon carcinogenesis. Cancer Res 59: 5093-5096.
49. Sonoshita M, Takaku K, Sasaki N, Sugimoto Y, Ushikubi F, et al. (2001) Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc(Delta 716) knockout mice. Nat Med 7: 1048-1051.
50. Mutoh M, Watanabe K, Kitamura T, Shoji Y, Takahashi M, et al. (2002) Involvement of prostaglandin E receptor subtype EP(4) in colon carcinogenesis. Cancer Res 62: 28-32.
51. Kitamura T, Itoh M, Noda T, Tani K, Kobayashi M, et al. (2003) Combined effects of prostaglandin E receptor subtype EP1 and subtype EP4 antagonists on intestinal tumorigenesis in adenomatous polyposis coli gene knockout mice. Cancer Sci 94: 618-621.